Chimaerism of FACS-sorted leucocyte subsets (CD14 þ , CD15 þ , CD3À/56 þ , CD3 þ /4 þ , CD3 þ /8 þ , CD19 þ ) was monitored prospectively between days þ 14 and þ 100 in 39 children undergoing allogeneic stem cell transplantation with reduced intensity-conditioning regimens. Cell subsets exceeding 1% of nucleated cells were subject to cell sorting. Chimaerism was analysed by dual-colour FISH and/or by short tandem repeat-polymerase chain reaction. The chimaerism pattern on day þ 28 was evaluated with regard to its correlation with graft rejection. Of 39 patients, nine patients had donor chimaerism (DC) in all subsets. Mixed/recipient chimaerism (MC/RC) was detectable within T cells in 62%, within NK cells in 39% and within monocytes and granulocytes in 38% of the patients. The correlation of secondary graft rejection with the chimaerism pattern on day þ 28 revealed the strongest association between RC in NK-cells (Po0.0001), followed by T cells (P ¼ 0.001), and granulocytes and monocytes (P ¼ 0.034). Notably, patients with RC in T cells rejected their graft only if MC or RC was also present in the NK-cell subset. By contrast, none of the children with DC in NK cells experienced a graft rejection. These observations suggest that, in the presence of recipient T-cell chimaerism, the chimaerism status in NK-cells on day þ 28 might be able to identify patients at high risk for late graft rejection.
Introduction
Bone marrow transplantation is the only curative therapy for a number of malignant and nonmalignant paediatric diseases. 'Immunological chimaerism' as evidence of bone marrow graft acceptance after transplantation has already been reported in the late 1970s, and Hansen et al were the first to publish chimaerism data concerning donor and recipient lymphocyte subpopulations after HLA-mismatched bone marrow transplantation. [1] [2] [3] Within the last few years, different methods have been established for quantitative or semiquantitative determination of chimaerism after stem cell transplantation (SCT). The most commonly used techniques are fluorescence in situ hybridisation (FISH) for sex chromosomes, and the polymerase chain reaction (PCR) to analyse the variable number of tandem repeats (VNTR) or short tandem repeats (STRs). [4] [5] [6] [7] In patients with malignant diseases, mixed chimaerism has been discussed by different authors as a predictive marker for early or late rejection and/or relapse. 8, 10 In patients undergoing SCT for nonmalignant diseases, mixed chimaerism is known to be a risk factor for late rejection. 9, [11] [12] [13] [14] [15] However, long-lasting stable mixed chimaerism is associated with cure in many patients. 3, 13 With the development of new approaches, such as SCT after nonmyeloablative conditioning, the interest in chimaerism and chimaerism kinetics has substantially increased. 16, 17 The first clinical trials using nonmyeloablative conditioning protocols were performed in elderly patients with haematological malignancies, not eligible for conventional myeloablative conditioning regimens. 18 In contrast to malignant diseases, pretransplant conditioning for nonmalignant disorders is not required to eradicate neoplastic clones, but has to be administered only to enable stable allogeneic stem cell engraftment.
Reduced intensity-conditioning (RIC) regimens are an attractive approach for children with nonmalignant diseases requiring stem cell transplantation. 19 By using RIC in children with nonmalignant diseases, transplant-related mortality can be reduced substantially even in high-risk patients. 19, 20 Since graft versus malignancy effect is not an issue in patients with nonmalignant disorders and graft-versus-host disease (GvHD) plays an important role in transplant-associated morbidity, prevention of GvHD by T-cell depletion is desirable. However, graft rejection following T-cell-depleted SCT remains the major adverse event in patients conditioned with RIC.
There is considerable evidence suggesting that chimaerism studies on sorted cell populations are more informative than investigation of total leucocyte populations with regard to a better predictive value for impending rejection, GvHD and relapse. [21] [22] [23] [24] [25] [26] [27] To address this issue, the present study examined the impact of early lineage-specific chimaerism of FACS-sorted leucocyte subsets on GvHD and late graft rejection following nonmyeloablative conditioning regimens in paediatric patients.
Patients and methods

Patients
Between March 1997 and May 2002, 69 patients received reduced intensity conditioning (RIC) prior to allogeneic stem cell transplantation at our centre. The conditioning protocol for patients with non-malignant diseases consisted of fludarabine, melphalan, total lymphoid irradiation and ATG. Patients with malignant diseases received RIC according to established protocols, if they were not eligible for conventional myeloablative conditioning protocols due to severe toxic or infectious preload. 28, 29 All patients with malignant diseases received T-cell-replete grafts. The following patients were excluded from the analysis:
1. Nine patients with severe combined immunodeficiency, because the preparative regimen for these patients consisted exclusively of ATG, and the post-transplant chimaerism pattern largely depends on the type of underlying immunodeficiency; 2. Two patients who died without detectable cells of donor origin (days þ 3 and þ 12) and one patient with Langerhans cell histiocytosis, who experienced a nonengraftment with autologous reconstitution; 3. 10 patients who died prior to day þ 100: eight of them displayed 100% donor chimaerism and one showed mixed T-cell chimaerism at the time of death (day þ 69); one patient with AML and mixed chimaerism died from progressive disease; 4. Eight patients who underwent RIC as secondary treatment following nonengraftment or early rejection after myeloablative conditioning. Five of the patients died transplantassociated with 100% donor chimaerism; two patients with nonmalignant diseases and one patient with CML are disease-free 4 years post-transplant.
A total of 39/69 patients who underwent SCT following RIC were eligible for analysis. Written informed consent was obtained from each patient and/or the parents, and the transplant protocols had been approved by the institutional review board of St Anna Children's Hospital. Median observation time was 21.6 months (range 4.2-70.6). Patient and donor characteristics, conditioning regimens, graft composition and GvHD prophylaxis are summarised in Table 1 .
Overall, 11 patients received donor lymphocyte infusions (DLI) between days þ 28 and þ 209 (median þ 51). Seven patients received a single DLI, three patients a second one after an interval of 3 weeks and one patient received a third DLI. 
Sample collection
Blood samples for chimaerism analysis were collected on days þ 7, þ 14, þ 28 and þ 35 post-transplant. Thereafter, in patients with sufficient T-cell engraftment (CD3 þ 41% of nucleated cells (NC) in peripheral blood) and complete donor chimaerism in all leucocyte subsets, the intervals were extended to 2 weeks, until day þ 100, and to 4 weeks thereafter. In patients with absent or insufficient T-cell engraftment until day þ 35, and in those who showed recipient chimaerism (RC) or mixed chimaerism (MC) in one or more cell subsets between days þ 14 and þ 35, chimaerism analysis was continued at a 7-day interval, until complete donor chimaerism was obtained in all cell subsets on two consecutive time points, or stable mixed chimaerism confirmed on four consecutive time points.
FACS analysis and cell sorting
The grafts and post-transplant patient blood samples were analysed by four-colour quantitative FACS analysis on the FACSCalibur (BD Biosciences) using a lyse-and-wash cellpreparation procedure. 30 The Paint-A-Gate software (BD) was employed for data evaluation. FACS sorting of leucocyte subpopulations on the FACSVantage SE (BD) was performed after three-colour staining in a lyse-and-wash procedure. All cell types exceeding 1% of NC were targets for cell sorting. Routinely sorted CD45 þ leucocytes included CD33 þ monocytes, CD15 þ granulocytes, CD3 þ /4 þ and CD3 þ /8 þ T cells, CD56 þ / CD3À NK cells and CD19 þ B cells. The number of target cells sorted for subsequent PCR or FISH analysis ranged between 1000 and 15 000. The purity of the sorted leucocyte fractions was generally 498%. Contaminating cells, if present, were usually derived from more than one cell population.
Chimaerism analysis
Specimens from patients transplanted from sex-mismatched donors (n ¼ 18) were analysed by FISH. Cells were dropped onto Underlying disease Leukaemia/non-Hodgkin's lymphoma Lineage-specific chimaerism in children S Matthes-Martin et al slides, air-dried and fixed with increasing concentrations of ethanol. Dual-colour FISH was performed according to standard procedures with commercially available probes specific for the centromeric and heterochromatic regions of the X and Y chromosomes, respectively. Depending on the number of cells available, up to 500 leucocytes were analysed in each sorted fraction.
The samples from patients with sex-matched donors (n ¼ 21) underwent PCR analysis. 31 Both methods were used simultaneously in eight patients. DNA was extracted from nucleated cells using the QIAamp Blood kit (Qiagen, Hilden, Germany).
Recipient and donor DNA were tested prior to transplantation by a panel of seven highly polymorphic STR markers to select an informative primer set suitable for the monitoring of chimaerism during the post-transplant course. For the analysis of patient/ donor origin of cells isolated by flow sorting, the amount of DNA serving as template in individual PCR reactions was generally in the range of 1-20 ng. Upon amplification by PCR, the alleles were quantified by two different approaches: (1) gel electrophoresis and video densitometry using the Kodak Digital Science System with the 1D Image Analysis Software (Kodak, Rochester, NY, USA); (2) capillary electrophoresis and fluorescence-based quantification using the ABI Prism 310 Genetic Analyser (Applied Biosystems, Foster City, USA).
In view of the fact that, depending on the recipient/donor sex constellation, two different methods of chimaerism analysis were used, chimaerism pattern was analysed on a semiquantitative basis, defining three chimaerism constellations in each cell subset:
( 
Definitions and clinical data
Nonengraftment was defined as the absence of donor cells following SCT in all cell lines. Detectable donor cells in at least one cell subset, but subsequent RC in all cell subsets before day þ 28, was referred to as early rejection. Late rejection was defined as RC in all cell subsets, following DC or MC in at least one subset prior to this time point. GvHD was graded using the Glucksman criteria. The chimaerism data on day þ 28 were correlated with in vivo T-cell depletion, graft composition (T-cell depleted vs unmanipulated) and clinical data, such as late rejection and GvHD.
Statistical analysis
Statistical analysis was performed using SAS (SAS/STAT s User's Guide, Version 8. 1999, SAS Institute Inc., Cary, NC, USA). To evaluate the correlation between the number of transplanted T and NK cells and chimaerism, Spearman correlation coefficients were calculated. To determine the correlation between the number of transplanted NK cells and NK-cell chimaerism, a logistic regression (SAS PROC LOGISTIC) was performed. Chimaerism on day þ 28 was identical in the CD3 þ /CD4 þ and the CD3 þ /CD8 þ populations in all but five patients, and in the monocyte and granulocyte populations in all but one patient. In all subsequent samples, chimaerism in the two T-cell subsets was identical. This was also the case in the monocyte and granulocyte populations. Hence, only the CD3 þ /CD8 þ T cells and the granulocyte population were used for the purpose of analysis.
To test for the correlations between T-cell depletion and donor type with late graft rejection, we applied Fisher's twosided exact test (SAS PROC FREQ). To determine the predictive values of the ordered categories RC, MC and DC in CD3 þ / CD8 þ T cells, NK cells and the myeloid population on rejection, Cochran-Mantel-Haenszel tests based on ridit scores (SAS PROC FREQ) were applied. P-values smaller than 0.05 were taken into account.
Results
Pattern of chimaerism in different lineages
In 30/39 (77%) patients, MC or RC was detectable in at least one leucocyte subset between days þ 14 and þ 35, and the remaining nine patients engrafted with stable DC in all cell subsets. Percentages of patients with RC, MC and DC in defined cell subsets on day þ 28 are given in Table 2 . The highest incidence of recipient or mixed chimaerism was observed in the T-cell populations. Among patients who had detectable T cells (41%) before day þ 28 (35/39), MC or RC was detectable in the CD3 þ /CD4 þ population in 77% and in the CD3 þ /CD8 þ population in 62%. However, analysis of T-cell chimaerism at the time of first T-cell increase showed a similar pattern in the CD3 þ /CD4 þ (77%) and in the CD3 þ /CD8 þ (66%) populations. Chimaerism analysis within the NK-cell compartment revealed RC or MC in 15 (39%) patients. In none of the patients with RC or MC in the NK-cell fraction, complete donor chimaerism was detected in the CD3 þ cell population. Conversely, among 24 children with DC in the NK-cell population, seven (29%) had MC and two (8%) had RC in the CD3 þ /CD8 þ cells.
In contrast to the T lymphocytes, the myeloid cell populations on day þ 28 were of complete donor origin in 62% of the patients with detectable T-cells (n=35). In all but three patients, the chimaerism patterns in the monocyte and granulocyte fraction were identical. B-cell chimaerism was evaluable for only 18 children on day þ 28: two patients (11%) had RC, six (33%) MC and 10 (56%) patients had DC.
Spearman correlation coefficients revealed that chimaerism in CD8 þ T cells and NK cells are strongly correlated (Po0.0001), chimaerism in granulocytes and monocytes showed a correlation with NK-cell chimaerism (P-value ¼ 0.0116), but no correlation with T-cell chimaerism (P-value ¼ 0.4000).
Distribution of chimaerism at different time points in the lineages investigated is shown in Figure 1 . Of 30 patients with stable graft, 25 showed complete donor chimaerism until day þ 100 in all cell subsets. One patient with SAA and three Table 2 Percentage of patients (number of patients) with RC, MC and DC in defined cell subsets on day +28 
Chimaerism in relation to pretransplant immunosuppression and graft composition
Owing to the limited patient number and the different conditioning regimens used, the statistical analysis of chimaerism patterns in relation to the different chemotherapeutic and irradiation regimens was not possible. Among the 21 patients transplanted with T-cell replete grafts, in vivo T-cell depletion was performed by adding ATG to the conditioning regimen from day À3 to À1 in 14 cases. There was no difference in the T-cell and the NK-cell chimaerism between patients who had received ATG and those who had not; in both groups, MC or RC was detectable in T cells and NK cells in 71 and 28%, respectively. As expected, SCT after ex vivo T-cell depletion was associated with a significantly higher incidence of RC in T cells, compared to SCT with unmanipulated grafts (Mantel-Haenszel test Pvalue ¼ 0.0016). Chimaerism analysis within the CD3 þ /CD8 þ cell population revealed RC in 1/21 (5%), MC in 11/21 (52%) and DC in 9/21 (43%) patients with T-cell-replete grafts vs RC in 10/14 (71%), MC in 0/14 and DC in 4/14 (29%) patients with Tcell-depleted grafts. Chimaerism analysis in the NK-cell compartment showed RC in 0/21, MC in 5/21 (24%) and DC in 16/21 (76%) patients with T-cell-replete grafts compared to RC in 5/18 (27%), MC in 5/18 (27%) and DC in 8/18 (44%) patients with T-cell-depleted grafts. The number of transplanted NK-cells did not correlate with NK-cell chimaerism on day þ 28 (P ¼ 0.33, Odds ratios: 1.02 (95% CI 0.98-1.05)). There was no correlation between in vivo or ex vivo T-cell depletion, and chimaerism within monocytes and granulocytes. Table 3 shows the Spearman correlation coefficients between the number of transplanted T cells and chimaerism on day þ 28, demonstrating that T-cell chimaerism was highly correlated, NK-cell chimaerism was borderline and myeloid chimaerism showed no correlation.
Graft-versus-host disease
The overall incidence of acute GvHD was 49%: GvHD grade III-IV was observed in nine (23%), and grade I-II in 10 (26%) patients. As expected, RC in CD8 þ T cells on day þ 28 was associated with the lowest incidence of GvHD: 9/11 (82%) patients did not develop GvHD, but seven of them experienced late graft rejection; 2/11 (18%) patients experienced GvHD; one developed grade II GvHD after conversion to MC in the T-cell population on day þ 40, and one developed grade IV GvHD following conversion to DC and occurrence of CMV viraemia on day þ 55.
Complete donor CD8 þ T-cell chimaerism on day þ 28 was not predictive for GvHD: GvHD grade I-II occurred in 3/13 (23%) patients with DC compared to 5/11 (45%) patients with MC; grade III-IV GvHD occurred in 3/13 (23%) patients with DC and in 4/11 (36%) with MC. However, at diagnosis of GvHD, grade III-IV GvHD occurred exclusively in the presence of DC in T cells: DC was associated with GvHD grade III-IV in 9/15 (60%) and with GvHD grade I-II in 6/15 (40%) patients; MC was associated with GvHD grade III-IV in 0/4 patients and with GvHD grade I-II in 4/4 patients.
None of the patients with RC in the NK cells experienced GvHD. There was a trend towards a lower overall incidence of GvHD in patients with MC in the NK cells: only 3/10 patients (30%) developed GvHD; however, two of them had GvHD grade III-IV. There was no correlation between chimaerism in the monocyte and granulocyte fractions and the incidence of GvHD. None of the patients with late graft rejection experienced GvHD.
Graft rejection
Of 39 patients, nine patients experienced secondary graft rejection between days þ 45 and þ 136 (median þ 72).
All but one patient with graft rejection showed complete autologous recovery in all lineages. In 7/9 patients, no aplasia was observed at the time of rejection, and the diagnosis was established exclusively by chimaerism analysis. Of nine patients, seven underwent a second SCT from the same unrelated donor (n ¼ 6) or from a second unrelated donor (n ¼ 1). All patients who underwent a second SCT engrafted successfully; two patients died transplant-associated on day þ 42 and þ 59, respectively. One patient with early Krabbe disease, who experienced rapid disease progression prior to the first SCT, and one patient with resistant renal cell carcinoma did not undergo a second transplant.
Of 11 patients, two (18%) with malignant diseases and 7/28 (25%) patients with nonmalignant disorders experienced graft rejection. Graft rejection occurred in 7/35 (20%) patients with HLA-identical or one AG-mismatched donors and in 2/4 (50%) patients with haploidentical donors (P-value ¼ 0.2226).
None of the 15 patients who received bone marrow and 2/6 (33%) patients who received unmanipulated peripheral blood stem cells rejected their grafts. There was a higher incidence of graft rejection in patients who had received T-cell-depleted grafts: rejection occurred in 7/18 (39%) patients with T-celldepleted grafts, but only in 2/21 (10%) with T-cell-replete grafts (P-value ¼ 0.055). The use of irradiation did not seem to have a significant influence on the incidence of graft rejection: Table 4 . One patient with RC in the monocyte fraction rejected his graft. However, rejection occurred in 6/10 (60%) patients with MC and in 3/29 (10%) patients with DC in granulocytes. Of 11 patients, seven (64%) patients with RC, 2/11 (18%) with MC and 0/13 patients with DC in the CD3 þ /CD8 þ cell population experienced graft rejection. Based on the evaluation of the chimaerism pattern at the time of first T-cell increase (median day þ 24, range 10-67), a similar incidence of rejection was observed in patients displaying RC, MC or DC within the CD3 þ /CD8 þ fraction (58, 11 and 0%). None of the patients without detectable T cells on day þ 28 experienced late graft rejection. All (5/5) patients with RC, 4/10 (40%) with MC and 0/24 patients with DC in the NK-cell population rejected their graft. As indicated by the Cochran-Mantel-Haenzel tests, the association between RC on day þ 28 and graft rejection showed the strongest correlation (P-value o0.0001) for NK cells, followed by RC in CD3 þ /CD8 þ T cells (P-value ¼ 0.001). Interestingly, in patients with RC or MC in the CD3 þ /CD8 þ cell subset, rejection occurred only in cases displaying either RC or MC in the NK cells. The incidence of rejection according to the different chimaerism patterns in T cells and NK cells is shown in Table 5 .
In contrast, chimaerism in granulocytes and monocytes was a less reliable predictor for graft rejection (P-value ¼ 0.034). Rejection rate according to chimaerism in leucocyte subsets on day þ 28 is shown in Figure 2 . (a) Transplant characteristics HLH (haemophagocytic lymphohistiocytosis), CGD (chronic granulomatous disease), ALL (acute lymphoblastic leukaemia), LCH (Langerhans cell histiocytosis); (b) distribution of chimaerism on day +28 (patients marked with asterisks received DLI). Table 5 Combination of chimaerism patterns in T-and NK-cells on day +28 and incidence of late graft rejection. (n ¼ 35; the four patients without T-cell engraftment until day +28 are not included) Rejection rate according to chimaerism in leucocyte subsets on day þ 28.
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In total, 11 patients, most of whom (n ¼ 8) had received Tcell-depleted grafts, were given DLI in the presence of mixed chimaerism in one or more leucocyte subsets; one patient with RC in T and B cells was treated with DLI for EBV-associated lymphoproliferative disease.
Prior to DLI, chimaerism analysis revealed DC (n ¼ 8) or MC (n ¼ 3) in granulocytes and monocytes, RC (n ¼ 7) or MC (n ¼ 4) in CD3 þ /CD8 þ T cells and RC (n ¼ 3), MC (n ¼ 5) and DC (n ¼ 3) in NK cells. Despite DLI, rejection occurred in 5/8 patients with DC and in 1/3 with MC in granulocytes and monocytes. Three of the patients remained stable mixed chimaerae (41, 28 and 20 months post DLI), whereas two converted to complete DC in all cell subsets. Of seven patients, four patients with RC and 2/4 patients with MC in the CD3 þ / CD8 þ T-cell population prior to DLI rejected their graft. However, all the three patients with RC, 3/5 patients with MC and none of the patients with DC in the NK-cell population experienced graft rejection following DLI. Chimaerism prior to DLI is summarised in Figure 3 .
Discussion
Chimaerism analysis in flow-sorted leucocyte subsets rather than in unseparated blood cells has a number of potential advantages. Increased sensitivity allows the detection of recipient cells even in leucocyte subsets with very low cell counts, which would not be detectable in the analysis of wholeblood specimens. 25, 32, 33 Concerning relapse after SCT in patients with leukaemia, the predictive value of mixed chimaerism in unfractionated peripheral blood has been discussed controversially. 34, 35 In patients with MC, lineage-specific chimaerism analysis might identify patients with incipient relapse by detection of increasing recipient signals in cell populations expected to harbour the leukaemia cell clone. [36] [37] [38] [39] In patients with nonmalignant diseases, MC can be associated with cure, depending on the specific cell line involved. 20, 40, 41 Following RIC regimens, MC is a common finding, with an incidence of 30-70%. 42, 43 In patients receiving RIC regimens, the impact of mixed chimaerism on rejection, GvHD, immune reconstitution and relapse presumably depends on the lineage affected and on the kinetics.
Selection of the time point (day þ 28) for evaluating the impact of lineage-specific chimaerism on late rejection and GvHD was based on two considerations:
(1) Even following myeloablative conditioning, cells of recipient origin were detectable between days þ 2 and þ 14 in most cases, and we and others have shown that the absence of donor cells until day þ 14 is predictive for early rejection or nonengraftment. 5, 10, 22 To evaluate the impact of chimaerism pattern on late rejection in patients receiving RIC, a time point beyond day þ 14 is preferable in order to exclude patients with nonengraftment or early rejection. (2) Day þ 28 seems to be the earliest clinically reasonable time point for the initiation of measures, such as modification of immunosuppression.
In our study, DC on day þ 28 was detected in 74% in the myeloid cells, but only in 26% of the lymphoid populations. This is consistent with the data published by Perez-Simon et al, 43 who found 89% DC in granulocytes between days þ 21 and þ 50 following non-myeloablative conditioning. A possible explanation for the high percentage of myeloid donor chimaerism might be the use of melphalan or low-dose busulphan in most patients, but data on patients conditioned with TBI 2 Gy and fludarabine reported by McSweeney et al 44 also revealed a higher percentage of DC in the myeloid compartment compared to the lymphoid cell compartments.
The high number of patients with RC or MC in T cells seems to be attributable to the fact that 46% of our patients received Tcell-depleted grafts and that the number of transplanted T cells correlated significantly with RC/MC in the lymphoid population. The correlation between T-cell depletion and recipient T-cell chimaerism on day þ 14 has already been described for patients undergoing myeloablative conditioning. 45 Sykes et al 46 found a predominance of donor lymphoid cells and varying levels of myeloid chimaerism between days þ 8 and þ 12 in five patients following RIC and T-cell-depleted SCT. 46 This observation may be attributable to the earlier time point of analysis.
Surprisingly, in vivo T-cell depletion by pretransplant ATG, administered in order to deplete host T cells, did not seem to have an impact on the pattern of T-cell chimaerism. In contrast to the data published by Schaap et al, 47 we found a strong correlation between NK-and T-cell chimaerism, although nine of 24 (38%) children with DC in the NK cells showed RC or MC in the T cells.
There was no statistically significant correlation between the number of infused NK-cells and NK-cell chimaerism. However, in view of the fact that T-cell depletion in this study was Lineage-specific chimaerism in children S Matthes-Martin et al performed by CD34 þ positive selection, implicating a strong association between T-cell and NK-cell depletion, this finding might be misleading. In an ongoing prospective trial at our centre performing T-cell depletion by CD3 þ /CD19 þ negative selection, the actual impact of the number of infused NK cells on chimaerism will be assessed.
Experimental as well as clinical data in adults suggest that mixed chimaerism is associated with a reduced incidence of GvHD by inducing stable graft-versus-host and host-versus-graft tolerance. 14, 24, 46, 48, 49 Mattsson et al 24 showed a significant correlation between early DC in T cells and GvHD in patients following myeloablative conditioning. In our paediatric patient cohort, T-cell chimaerism on day þ 28 did not seem to have a predictive value for the incidence and severity of GvHD, especially if patients with subsequent rejection were censored. This is in line with the results published by Valcarcel et al. 50 Furthermore, the lack of correlation might be due to the fact that 46% of our patients received T-cell-depleted grafts. In the study performed by Mattsson et al, none of the patients seemed to have RC in the T-cell fraction. The use of reduced intensity conditioning in our patient cohort and the relatively high number of patients with RC in the T-cell population may explain the difference.
In the study by Childs et al 21 reporting the kinetics of lineagespecific chimaerism in 15 patients following RIC and transplantation with a T-cell-replete graft, 100% donor T-cell engraftment always preceded GvHD.
Interestingly, in our patient cohort, analysis of T-cell chimaerism at the time of GvHD revealed MC in four patients. However, none of the patients with MC developed grade III-IV GvHD, and DC in the T-cell population at the time of GvHD was associated with grade III-IV GvHD in nine cases.
Rejection did not correlate significantly with use of ATG or irradiation-containing conditioning protocols and the degree of HLA match. However, the latter might be due to the small number of patients receiving haploidentical grafts. As shown by others in the context of both myeloablative conditioning and RIC, T-cell depletion was associated with an increased incidence of graft failure or rejection. 48, 51, 52 In contrast to the data published by Gö rner et al, 53 who reported successful longterm engraftment in 5/6 patients with T-cell-depleted grafts following TBI 2 Gy plus fludarabine, the rejection rate in patients with this very mild conditioning regimen was 40% in our patient cohort. One explanation might be that all but two patients suffered from nonmalignant diseases and therefore had no prior high-dose chemotherapy.
Chimaerism in monocytes and granulocytes on day þ 28 had no prognostic impact with regard to late rejection. Following T-cell-depleted SCT, these two populations usually represented between 92 and 95% of the nucleated cells on day þ 28 in patients following myeloablative conditioning or RIC (data not shown).
These findings, as well as the fact that all patients with late graft rejection showed 44-94% overall donor chimaerism on day þ 28, suggest that chimaerism analysis of whole-blood NC might be misleading with regard to the risk of late graft rejection, especially in patients receiving T-cell-depleted grafts.
None of the patients with DC in the T-cell population experienced late graft rejection, whereas RC showed a significant correlation with the incidence of rejection. Despite a significantly higher incidence of rejection in patients with RC in the T-cell population, donor T-cell chimaerism does not seem to be a prerequisite for stable engraftment: four/11 patients with RC and 10/11 patients with MC did not reject their grafts. However, all patients with RC and none of the patients with DC in the NK-cell population experienced late graft rejection, and the correlation between NK-cell RC and late graft rejection was highly significant.
The response to DLI in our study determined by chimaerism analysis was comparable to that reported by Marks et al. 54 Interestingly, 4/4 patients with RC or MC in the T-cell population and RC in the NK-cell subset rejected their graft despite DLI. However, due to the small patient number, this finding should be interpreted with caution. Bornhäuser et al 55 reported less than 75% donor NK-cells between days þ 10 and þ 30 in 3/4 patients with graft rejection following dose-reduced conditioning.
The presence of NK-cells in children with severe combined immunodeficiency (T-B-SCID) is known to be associated with a diminished engraftment rate. 56 Moreover, a number of experimental studies have shown that the depletion of host NK cells facilitates engraftment, following both myeloablative and nonmyeloablative conditioning protocols. [57] [58] [59] [60] Of nine patients, seven patients with late graft rejection had received HLA-identical grafts, suggesting that mechanisms other than the classical HLA-mismatch-related NK-cell alloreactivity described by Ruggeri et al 61 may be involved. The role of NK cells in HLA-identical SCT following RIC has not yet been determined. Two opposite mechanisms are conceivable: resistance of recipient NK-cells to pretransplant immunosuppression resulting in rejection, or the presence of donor NK cells facilitating engraftment. 62, 63 Allo-recognition might be mediated by KIR disparities, independent of classical HLA class I molecules, or by nonclassical HLA-determinants. 64, 65 The impact of KIR polymorphism on the outcome of HLA-identical SCT following myeloablative conditioning has been described. 64, 66 In the context of RIC with persisting recipient haematopoietic cells KIR disparities might contribute to rejection.
All patients with late graft rejection had MC or RC on day þ 28, not only in T cells but also in NK cells. By contrast, patients with RC in T cells and DC in NK cells did not reject their grafts. It has been shown for a number of infectious organisms and tumour cells that NK-cell and T-cell interactions result in an increase in cytokine release and cytotoxicity. [67] [68] [69] [70] Our clinical observations suggest that, in the presence of recipient T-cell chimaerism, the chimaerism status in NK cells might be able to discriminate patients at risk for late graft rejection from those with stable grafts.
